Abstract 2781: De novo molecular mechanisms of resistance to mobocertinib
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/1538-7445.am2022-2781
Abstract: Mobocertinib is an oral tyrosine kinase inhibitor recently approved by the FDA for the treatment of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon… read more here.
Keywords: response; response mobocertinib; egfr exon; amplification ... See more keywords